Clinical Trial Update: A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating LYT-200 in adults with relapsed/refractory acute myeloid leukemia or relapsed/refractory high-risk myelodysplastic syndrome; recruitmen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• LYT-200 (LYT-200)

Snippet

Sponsor: PureTech | Conditions: AML, Adult Recurrent, MDS | Phase 1 | Status: RECRUITING